Análisis de la acción MaxCyte Inc (MXCT)

Análisis de IA of MaxCyte Inc (MXCT)

Mantener

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.

Métricas de valoración

El PER previsto actual de MaxCyte Inc (MXCT) es 0.00, frente a su media de 5 años de -13.28.

PER previsto

Sobrevalorado

Media 5A P/E

-13.28

P/E actual

0.00

Sobrevalorada

-3.68

Infravalorada

-22.87

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-9.98

EV/EBITDA actual

-3.07

Sobrevalorada

1.46

Infravalorada

-21.43

Precio/ventas previsto

Infravalorado

Media 5A P/S

9.43

P/S actual

3.86

Sobrevalorada

14.36

Infravalorada

4.49

Escenarios de precio de Alphio AI para MXCT

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%MXCT

$2.88

Precio del escenario

B

Base

Base · 50%MXCT

$2.21

Precio del escenario

B

Bajista

Bajista · 25%MXCT

$1.63

Precio del escenario

Ballenas con MXCT en cartera

A

Apollo Global Management, Inc.

+ Con en carteraMXCT

-2.44%

Rentabilidad a 3 meses

Preguntas frecuentes sobre MXCT, respondidas por Alphio AI

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.